Terns Pharmaceuticals to Present Positive Preclinical Data on FXR Agonist TERN-101 at The Liver Meeting® 2019
15.10.2019 12:00:00 EEST | Business Wire | Press release
Terns Pharmaceuticals, Inc., a global biopharmaceutical company focused on discovering and developing innovative therapies to treat non-alcoholic steatohepatitis (NASH) and cancer, today announced it will present preclinical study results on the farnesoid X receptor (FXR) agonist TERN-101 at The Liver Meeting® 2019, being held by the American Association for the Study of Liver Diseases (AASLD) in Boston, MA., November 8-12. The data demonstrate that in preclinical models, TERN-101 was preferentially delivered to the liver, which enables a robust, localized effect on FXR, while potentially mitigating non-liver mediated adverse effects.
The abstract (#2158), titled “Pharmacokinetics, tissue distribution and pharmacodynamics of TERN-101, a novel farnesoid X receptor (FXR) agonist, in preclinical species” will be presented as a poster on Monday, November 11, 2019.
“TERN-101 has the potential to be the backbone of future combination treatments for NASH due to its broad pleiotropic effects of FXR agonism on multiple pathogenetic mechanisms of NASH,” said Erin Quirk, M.D., Chief Medical Officer of Terns. “Our preclinical data show that TERN-101 is efficiently enriched in the liver, the target organ for FXR activity against NASH, which could potentially mitigate non-liver mediated tolerability issues associated with systemic FXR activation.”
TERN-101 has been advanced into clinical studies. A Phase 1 trial demonstrated clinical pharmacokinetic properties consistent with once-daily dosing. At The International Liver Congress™ 2019 in Vienna, Terns presented preclinical data demonstrating that TERN-101 reduced liver steatosis, inflammation, ballooning, and fibrosis in a preclinical model of non-alcoholic steatohepatitis (NASH).
TERN-101 and TERN-201, a semicarbazide-sensitive amine oxidase (SSAO) inhibitor, are both in development for the treatment of NASH and were initially discovered and developed by Eli Lilly and Company. Terns signed a global, exclusive agreement with Eli Lilly in 2018 to develop, manufacture, and commercialize TERN-101, TERN-201, and another preclinical candidate that inhibits an undisclosed NASH target.
About TERN-101 and Farnesoid X Receptor (FXR) Agonism
TERN-101 is a potent non-bile acid FXR agonist being developed as a therapeutic for NASH. FXR is a nuclear receptor that is highly expressed in the liver and small intestine. Bile acids (BA) are natural ligands of FXR, and their binding with and activation of FXR is critical to the regulation of cellular pathways that modulate BA synthesis, lipid metabolism, inflammation, and fibrosis. FXR agonism and activation has demonstrated improvement over placebo in regression of histological liver fibrosis without progression to NASH in a late-stage study, demonstrating the potential for FXR agonists to be a new treatment modality for NAFLD and NASH.
About NASH
Non-alcoholic steatohepatitis (NASH) is a severe form of non-alcoholic fatty liver disease (NAFLD), which is caused by the accumulation of excess fat in the liver. NASH is associated with chronic liver inflammation and liver cell injury, and it can lead to fibrosis, cirrhosis, and eventually liver cancer or liver failure. Global rates of NAFLD and NASH are increasing rapidly, in tandem with rising rates of obesity. There is currently no approved medication for the treatment of NASH.
About Terns Pharmaceuticals
Terns Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company that is focused on the discovery and development of medicines for chronic liver disease and cancer. Based in China and the United States, the company is advancing a pipeline of drug candidates for the treatment of non-alcoholic steatohepatitis (NASH) and cancer, across multiple modalities. Terns leverages world class expertise in disease biology, medicinal chemistry, and clinical development in order to bring promising new therapies to patients in China and other global markets.
For more information, visit www.ternspharma.com and www.ternspharma.com.cn
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191015005032/en/
Contact information
US Media Contact:
Margaret Robinson
+1 (415) 690 0084
China Media Contact:
Zhou Zhou
+86 13482103703
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
TestMu AI Introduces DevTools Assertions in Kane CLI, Enabling Browser-Level Validation Through Natural Language16.6.2026 15:30:00 EEST | Press release
TestMu AI (formerly LambdaTest), the world's first Agentic AI-powered Quality Engineering platform, today announced DevTools Assertions for Kane CLI, enabling developers and AI agents to validate browser internals using natural language. Traditional browser automation focuses on what users can see: buttons, forms, text, and visual states. However, modern web applications depend heavily on browser activity that remains invisible to users, including network requests, API responses, console logs, cookies, local storage, and performance metrics. With DevTools Assertions, Kane CLI extends browser validation beyond the UI, allowing teams to verify these underlying signals using plain-English objectives. Developers can now write objectives such as: "Click Add to Cart and assert the request to /api/cart returned status 200." "Run the checkout flow and assert the console has no errors." "Log in and store the session cookie value." "Assert localStorage contains the selected product ID." "Open th
Allegro DVT’s Pulsar Decoder IP Adds Support for AV2 Video Codec16.6.2026 15:30:00 EEST | Press release
Allegro DVT, the leader in Semiconductor Video IPs and Video Compliance Tools, announces the availability its real-time AV2 Decoder IP integrated into its Pulsar™ D400 Series Multi-Standard Decoding IP. This milestone is a follow-up to the company’s announcement in September 2026 that underscored its plans to develop solutions for the emerging AV2 ecosystem spanning both video compliance tools and semiconductor IPs. As global demand for high-quality streaming continues to accelerate, AV2 is emerging as the next major open, royalty-free video compression standard. Developed by the Alliance for Open Media (AOM), AV2 represents a generational leap in video coding, designed to address evolving streaming requirements and enable new media experiences. Building on the success of AV1, AV2 introduces capabilities that support advanced applications such as immersive content (AR/VR), multi-view and split-screen streaming, and improved screen content handling, while operating across a wider range
Sai Life Sciences Achieves EcoVadis Platinum Rating, Joining the Top 1% of Companies Assessed Worldwide16.6.2026 15:27:00 EEST | Press release
Sai Life Sciences Limited (BSE: 544306 | NSE: SAILIFE), one of India’s leading integrated contract research, development, and manufacturing organizations (CRDMOs) has secured the EcoVadis Platinum Rating 2026, placing it among the top 1% of companies assessed worldwide for sustainability performance. With an overall score of 87/100 and a 99th percentile ranking, Sai Life Sciences has achieved Platinum Medal in ‘Manufacture of Basic Pharmaceutical Products and Pharmaceutical Preparations’ category. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260616260047/en/ Sai Life Sciences achieves EcoVadis Platinum Rating, joining the top 1% of companies assessed worldwide Making the announcement, Krishna Kanumuri, CEO & Managing Director, Sai Life Sciences, said, “Sustainability is becoming one of the defining measures of excellence in our industry. The ability to innovate, grow and create impact must be matched by an equal commitment
Plaud Scales From $1M to $100M ARR Within Two Years, Bringing AI Beyond the Screen for Professionals16.6.2026 15:25:00 EEST | Press release
Plaud, the company building real-world AI interface for professionals, today announced it has scaled from $1M to $100M in ARR within two years, placing it among the fastest AI companies globally to reach the milestone. Plaud is the only hardware-enabled AI company in a cohort otherwise dominated by software-only players, and now serves more than 2 million professionals across 170+ countries. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260616945160/en/ The fastest AI growth stories have, until now, belonged almost entirely to software-native companies: AI coding tools, enterprise workflow agents, and other SaaS products scaling behind screens and keyboards. Plaud's growth represents a different model — recurring AI software scaled through a real-world physical interface, with devices (Plaud Note, Plaud Note Pro, Plaud NotePin S) acting as the entry point into human conversations, capturing the upstream, lossless, source-of
Rehlko Integrates WB Power Services into its UK and EMEA Platform, Expanding Lifecycle Capabilities for Mission-Critical Power16.6.2026 15:00:00 EEST | Press release
Rehlko, a global energy resilience leader delivering innovative solutions across industrial energy systems, powertrain technologies, and home energy applications, today announced that its UK business, formerly WB Power Services, has been fully brought onto the Rehlko platform, strengthening the company’s UK and Europe, Middle East, and Africa (EMEA) operating model and expanding its ability to deliver end-to-end lifecycle solutions for mission-critical power applications. The move aligns the former WB Power Services’ long-established UK capabilities – including engineering, installation, commissioning, and long-term service – with Rehlko’s broader platform. It represents an important step in scaling consistent, high-quality delivery across priority markets as demand accelerates in data centers and other mission-critical environments. Customers increasingly require partners that can deliver reliable, repeatable solutions across the full project lifecycle and over long operating horizons
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom